ORIENT BIO Inc. (002630.KS)
KRW 967.0
(-14.65%)
KRW 967.0
(-14.65%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 28 Billion KRW | 0.0% |
| 2022 | 28.81 Billion KRW | 9.68% |
| 2021 | 26.27 Billion KRW | -49.49% |
| 2020 | 52.02 Billion KRW | 37.99% |
| 2019 | 37.69 Billion KRW | 24.12% |
| 2018 | 30.37 Billion KRW | -74.94% |
| 2017 | 121.2 Billion KRW | 11.18% |
| 2016 | 109.01 Billion KRW | 3.78% |
| 2015 | 105.04 Billion KRW | 12.1% |
| 2014 | 93.7 Billion KRW | 11.93% |
| 2013 | 83.72 Billion KRW | 8.76% |
| 2012 | 76.98 Billion KRW | 47.89% |
| 2011 | 52.05 Billion KRW | 8.06% |
| 2010 | 48.17 Billion KRW | 7.68% |
| 2009 | 44.73 Billion KRW | 4.52% |
| 2008 | 42.8 Billion KRW | -2.4% |
| 2007 | 43.85 Billion KRW | 95.34% |
| 2006 | 22.45 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 7.38 Billion KRW | 23.89% |
| 2023 Q4 | 5.96 Billion KRW | -27.18% |
| 2023 Q3 | 8.18 Billion KRW | 27.66% |
| 2023 FY | 28.81 Billion KRW | 0.0% |
| 2023 Q1 | 7.02 Billion KRW | 17.81% |
| 2023 Q2 | 6.41 Billion KRW | -8.7% |
| 2022 Q2 | 7.77 Billion KRW | 10.8% |
| 2022 FY | 28.81 Billion KRW | 9.68% |
| 2022 Q4 | 5.96 Billion KRW | -26.13% |
| 2022 Q3 | 8.06 Billion KRW | 3.79% |
| 2022 Q1 | 7.01 Billion KRW | 0.0% |
| 2021 Q3 | 17.21 Billion KRW | 18.87% |
| 2021 FY | 26.27 Billion KRW | -49.49% |
| 2021 Q1 | 13.5 Billion KRW | -2.88% |
| 2021 Q2 | 14.47 Billion KRW | 7.25% |
| 2020 Q4 | 13.9 Billion KRW | -1.65% |
| 2020 FY | 52.02 Billion KRW | 37.99% |
| 2020 Q1 | 11.97 Billion KRW | 1.43% |
| 2020 Q2 | 12.01 Billion KRW | 0.37% |
| 2020 Q3 | 14.13 Billion KRW | 17.64% |
| 2019 Q1 | 7.61 Billion KRW | 111.11% |
| 2019 FY | 37.69 Billion KRW | 24.12% |
| 2019 Q3 | 10.46 Billion KRW | 33.79% |
| 2019 Q2 | 7.82 Billion KRW | 2.7% |
| 2019 Q4 | 11.8 Billion KRW | 12.79% |
| 2018 FY | 30.37 Billion KRW | -74.94% |
| 2018 Q3 | 35.65 Billion KRW | 10.79% |
| 2018 Q4 | -68.56 Billion KRW | -292.31% |
| 2018 Q1 | 31.1 Billion KRW | 4.61% |
| 2018 Q2 | 32.18 Billion KRW | 3.47% |
| 2017 FY | 121.2 Billion KRW | 11.18% |
| 2017 Q2 | 30.35 Billion KRW | 4.07% |
| 2017 Q3 | 31.94 Billion KRW | 5.24% |
| 2017 Q1 | 29.16 Billion KRW | 0.86% |
| 2017 Q4 | 29.73 Billion KRW | -6.94% |
| 2016 FY | 109.01 Billion KRW | 3.78% |
| 2016 Q2 | 24.25 Billion KRW | -7.02% |
| 2016 Q3 | 29.75 Billion KRW | 22.65% |
| 2016 Q4 | 28.91 Billion KRW | -2.8% |
| 2016 Q1 | 26.08 Billion KRW | -4.3% |
| 2015 Q1 | 24.99 Billion KRW | 5.34% |
| 2015 Q4 | 27.26 Billion KRW | -2.7% |
| 2015 Q3 | 28.01 Billion KRW | 13.1% |
| 2015 FY | 105.04 Billion KRW | 12.1% |
| 2015 Q2 | 24.77 Billion KRW | -0.91% |
| 2014 Q3 | 24.29 Billion KRW | 6.68% |
| 2014 Q1 | 22.92 Billion KRW | -5.61% |
| 2014 FY | 93.7 Billion KRW | 11.93% |
| 2014 Q2 | 22.76 Billion KRW | -0.66% |
| 2014 Q4 | 23.73 Billion KRW | -2.3% |
| 2013 Q2 | 18.47 Billion KRW | -7.28% |
| 2013 FY | 83.72 Billion KRW | 8.76% |
| 2013 Q4 | 24.28 Billion KRW | 15.45% |
| 2013 Q3 | 21.03 Billion KRW | 13.82% |
| 2013 Q1 | 19.92 Billion KRW | -3.29% |
| 2012 FY | 76.98 Billion KRW | 47.89% |
| 2012 Q2 | 19.03 Billion KRW | 25.46% |
| 2012 Q3 | 22.17 Billion KRW | 16.5% |
| 2012 Q4 | 20.6 Billion KRW | -7.05% |
| 2012 Q1 | 15.16 Billion KRW | 0.0% |
| 2011 Q3 | 4.99 Billion KRW | 16.33% |
| 2011 Q2 | 4.29 Billion KRW | 2.81% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 Q1 | 4.17 Billion KRW | 0.0% |
| 2011 FY | 52.05 Billion KRW | 8.06% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 Q1 | 4.42 Billion KRW | 0.0% |
| 2010 Q2 | 5.78 Billion KRW | 30.93% |
| 2010 Q3 | 5.02 Billion KRW | -13.17% |
| 2010 FY | 48.17 Billion KRW | 7.68% |
| 2009 Q1 | 4.3 Billion KRW | 0.0% |
| 2009 Q2 | 4.76 Billion KRW | 10.65% |
| 2009 Q3 | 4.35 Billion KRW | -8.43% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 FY | 44.73 Billion KRW | 4.52% |
| 2008 Q1 | 4.38 Billion KRW | 0.0% |
| 2008 Q3 | 4.55 Billion KRW | -11.95% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 FY | 42.8 Billion KRW | -2.4% |
| 2008 Q2 | 5.17 Billion KRW | 17.93% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 FY | 43.85 Billion KRW | 95.34% |
| 2007 Q1 | 3.46 Billion KRW | 0.0% |
| 2007 Q3 | 5.81 Billion KRW | 78.57% |
| 2007 Q2 | 3.25 Billion KRW | -6.1% |
| 2006 FY | 22.45 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Green Cross Holdings Corporation | 2057.93 Billion KRW | 98.639% |
| Green Cross Holdings Corporation | 1626.64 Billion KRW | 98.278% |
| Pharmicell Co., Ltd. | 56.22 Billion KRW | 50.193% |
| Green Cross Corporation | 1626.64 Billion KRW | 98.278% |
| GeneOne Life Science, Inc. | 40.2 Billion KRW | 30.341% |
| Celltrion, Inc. | 2176.43 Billion KRW | 98.713% |
| Samsung Biologics Co.,Ltd. | 3694.58 Billion KRW | 99.242% |
| SK bioscience Co.,Ltd. | 369.5 Billion KRW | 92.421% |
| SK Biopharmaceuticals Co., Ltd. | 354.89 Billion KRW | 92.109% |
| Prestige BioPharma Limited | 689.07 Million KRW | -3964.162% |